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FORGING A LANDMARK CAREER
Professor Hong was born on August 13, 1942 as the sixth of sev-
en children, while Korea was still under Japanese colonial rule. 
He credits his late brother, Suk Ki Hong, MD, PhD, a professor 
at New York State University who used to be a chair of the De-
partment of Physiology at Yonsei University College of Medi-
cine and made significant scientific contributions in renal physi-
ology and diving medicine, for influencing Professor Hong to 
pursue a career in medicine.1 He received his medical degree 
in 1967 from the Yonsei University College of Medicine in 
Seoul. When Professor Hong and his wife, Mihwa, who was 8 
months pregnant at the time, made the journey from Korea to 
Manhattan, New York in 1970, he had just $451 in his wallet, and 
the only job he could get was as an intern at the Bronx-Leba-
non Hospital Center, a community hospital in the Bronx.1
Working as an intern was grueling—24-hour shifts every two 
nights—and his lack of proficiency in English made it difficult 
to communicate clearly with his patients and members of the 
hospital staff. After completing his internship, he applied to 
hundreds of hospitals in the state but received few responses, 
obtaining only one letter of recommendation from an orthope-
dic surgeon he had assisted during surgery by holding clamps 
for 5 to 6 hours. The surgeon wrote a two-paragraph letter 
which essentially stated that “this guy assisted with my opera-
tions and is very strong at holding clamps.” Professor Hong said 
this might have been pretty discouraging to most people, not-
ing that he had to continue applying for almost a year before 
landing a residency at the Boston Veteran’s Affairs (VA) Medi-
cal Center. However, during residency at the Boston VA Medi-
cal Center, Professor Hong found his calling in oncology. He 
said, “I realized that I wasn’t that good. I experienced major 
hardships, especially during my first 3 years as a foreigner. I 
had to overcome language and cultural barriers. It was tough. 
Fortunately, I was tough enough to overcome the challenges 
in the environment.”1 In Professor Hong’s view, there is no 
hopelessness, only hope. After deciding to specialize in oncol-
ogy, he was accepted into a fellowship program at the Memo-
rial Sloan Kettering Cancer Center (MSKCC), where his men-
tors included Burton Lee, MD, Irwin Krakoff, MD, and Robert 
Wittes, MD.2 It was while at MSKCC that he developed a pas-
sion for research and academia—two professional loves that 
would become the cornerstones of his work. After finishing his 
fellowship in 1975, he returned to the Boston VA Medical Cen-
ter as the Chief of Medical Oncology, where his original men-
tor, Dr. Joel Caslowitz, was present, and became a faculty 
member at both the Boston University School of Medicine and 
the Tufts University School of Medicine. He established one of 
the best medical oncology programs in Boston, which com-
prised 13 board-certified medical oncologists. He led the land-
mark Veterans Administration Cooperative Laryngeal Cancer 
Study Group’s induction chemotherapy and radiotherapy trial 
for laryngeal preservation, which changed the way the disease 
is managed and served as a model for organ preservation for 
many other types of cancer.3 The study results were published 
in The New England Journal of Medicine (NEJM) in 1991. “I 
learned the larynx preservation technique from my mentor at 
MSKCC, Robert Wittes, MD, so I have to give him credit,” said 
Professor Hong. “I was always behind; I started at the bottom. 
However, it is not important who starts first. It is important 
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who finishes first,” he added. Professor Hong noted that, of 
the 14 members in his fellowship program, he was the first to 
become a full professor at the age of 42 years. Thus, he beat the 
odds of his cohort.1 
USHERING IN A NEW ERA 
OF PERSONALIZED MEDICINE
In 1984, Professor Hong was recruited by Irwin H. Krakoff, 
MD, head of the Division of Medicine at MD Anderson Cancer 
Center (MDACC) and a mentor during his fellowship training 
at MSKCC. Professor Hong stayed at MDACC for the next 30 
years, serving as the chair of the Thoracic/Head and Neck 
Medical Oncology Department, head of the Cancer Medicine 
Division, and the Vice Provost for Clinical Research. It was at 
MDACC that Professor Hong began a new historical chapter in 
his work after realizing the power of multidisciplinary re-
search and of having access to high-quality scientific collabora-
tors.4 With the support of the National Cancer Institute in 1986, 
he established a large multidisciplinary research program to 
focus on chemoprevention in the aerodigestive tract.5 This 
project published research results in 1986, 1990, 1993, and 1995 
in NEJM, contributing to defining a new discipline in cancer 
prevention and cancer interception strategy. In 2004, he de-
veloped a new paradigm of personalized cancer therapy with 
his work on the landmark Biomarker-integrated Approaches 
of Targeted Therapy for Lung Cancer Elimination trial, which 
ushered in a new era of precision medicine.1 
As the head of Cancer Medicine, Professor Hong supervised 
17 academic departments and more than 350 faculty mem-
bers. He established a premier cancer medicine program across 
the board, training more than 200 clinical fellows. “To survive 
in academia, you have to have a passion, resilience, persever-
ance, and patience,” explained Professor Hong.6 He trans-
formed MDACC into a hotbed of collaborative translational 
research and, as part of his legacy, MDACC today boasts an 
enormous patient volume; magnificent cutting-edge, biomark-
er-driven translational trials; more federal funding in cancer 
than any other institutions over the last decade; and a rich pipe-
line of exceptional physician-scientists.2 He played a leadership 
role in shaping public policy through his service as the chair 
of the Prevention, Clinical, and Therapeutic Subcommittee 
for the National Cancer Institute (NCI) External Board of Sci-
entific Advisors (BSA); the NCI Translational Research Work-
ing Group; the United States Food and Drug Administration 
Oncologic Drug Advisory Committee; and the Subcommittee 
of Clinical Investigations for the National Cancer Advisory 
Board. He was appointed by President George W. Bush to 
serve on the National Cancer Institute’s National Cancer Ad-
visory Board, and was also elected as a member of the U.S. 
National Academy of Medicine. Similarly, he was also made a 
member of the National Academy of Medicine in Korea. Ap-
pointment as an elected member to the Institute of Medicine 
(IOM) of the National Academies is considered one of the 
highest honors in the fields of health and medicine, and it rec-
ognizes individuals who have demonstrated outstanding pro-
fessional achievements and commitment to service. Professor 
Hong has been recognized with numerous awards, including 
the Medal of Honor for Clinical Research from the American 
Cancer Society, the Raymond Bourgine Award and the Claude 
Jacquillat Award from the International Congress on Anti-can-
cer Treatment in France, the Joseph A. Burchenal and Rosen-
thal Foundation Awards from the American Association for 
Cancer Research (AACR), the David Karnofsky Memorial 
Award from the American Society of Clinical Oncology, the Ex-
patriate Award from the Korean Broadcasting System, the Ho-
Am Prize in Medicine from the Samsung Foundation, the Proud 
Korean Award from the Korean American Leadership Founda-
tion, the Proud Alumni Award from Yonsei University, and a 
Lifetime Achievement Award from the Korean American Med-
ical Association. He served as the first-ever Asian-American 
President of the AACR (2001–2002) and as an inaugural fellow 
of the AACR academy.6 He said, “If you don’t forget where you 
came from, if you honor the past and stay hopeful about the 
future, you can accomplish anything. As a boy growing up in 
Korea who dreamed of coming to the land of opportunity, I 
never could have imagined I would achieve so much.”1 The city 
of Houston designated August 15, 2014 as “Waun Ki Hong Day” 
by mayoral decree to celebrate the Festschrift of Lifetime Ac-
complishments of a Great Leader.2 Professor Hong loved base-
ball, especially the Red Sox. When he threw the first pitch at 
Fenway Park, which is the Red Sox’s ball park, the city of Bos-
ton proclaimed May 22, 2015 as “Waun Ki Hong Day.” Profes-
sor Hong often liked to use baseball terms when he talked to his 
colleagues and trainees. “Don’t try to hit a home run at the 
start—just go for a small hit. In sports, you have to give credit to 
your teammates; it’s the same in academia.”1 
AACR announced the AACR–Waun Ki Hong Award for Out-
standing Achievement in Cancer Research.4 The award seeks 
not only to recognize a worthy cancer researcher who has con-
ducted highly meritorious laboratory, translational, or clinical 
cancer research under the age of 46 years, but also to honor 
Professor Hong for his lifelong mentorship and support of the 
careers of young cancer researchers. In April 2017, at the AACR 
Annual Meeting in Washington, D.C., the first award was pre-
sented to Roger S. Lo, MD, PhD, a professor in the Division of 
Dermatology and an associate professor in the Department of 
Molecular and Medicinal Pharmacology at the David Geffen 
School of Medicine at the University of California, Los Angeles. 
Professor Hong said, “Aiming high and seeing the big picture. 
You have to ask yourself at the end of the day—are you proud of 




DEDICATION TO ALA MATER, SEVRANCE
Professor Hong retired as the head of Cancer Medicine at the 
age of 72 years, but continued his important work with MDACC 
in a postretirement position within the Sheikh Khalifa Bin Za-
yed Al Nahyan Institute for Personalized Cancer Therapy and 
as part of the Advanced Scholar Program within Cancer Med-
icine.5 He remains cherished as a mentor and an individual 
who left behind a legacy for us to appreciate.7 During his ca-
reer, he trained more than 200 fellows from 18 countries, in-
cluding China, Japan, Italy, France, and Spain.5 Most notably, 
he never forgot where he came from, and has given back so 
much to his homeland. As a result, more than 100 of his train-
ees were from Korea, with about 20 of them now acting as di-
rectors of cancer centers or leaders of cancer society in Korea.3 
“Mentoring is my passion,” said Professor Hong. “My era will 
soon be gone. You have to bring up the next generation of sci-
entists and have a strong pipeline of talented people to suc-
ceed you; that results from mentorship.”5 
Professor Hong worked hard with pride and integrity as a 
proud Korean-American, especially as a Yonsei University 
alumni. In 2000, he received an honorary D.M.Sc degree from 
Yonsei University with the Grand Prize in Medicine (Fig. 1). 
He has left a wonderful legacy at MDACC as a dedicated can-
cer researcher with a Korean heritage. To demonstrate his 
special affection toward his alma mater, starting in 2005, he 
led the External Advisory Board that culminated in the estab-
lishment of Yonsei Cancer Center. After being appointed as a 
special advisor to Yonsei University in 2014 to provide core 
strategies for Yonsei University and Yonsei Cancer Center, 
Professor Hong shared the latest global trend of research and 
proposed its application plan for Yonsei University (Figs. 2 
and 3). Moreover, he helped to train young researchers at his 
alma mater. He provided opportunities to students at Yonsei 
University and helped young medical scientists to gain expe-
rience at the MDACC, as well as full material and emotional 
support, to help them adapt to the new surroundings.4 Like-
wise, he visited his alma mater in 2017 and donated $100000 
worth of scholarship grants for medical students. His other 
key contributions to Severance Hospital included inviting 
Yonsei representatives to the GAP 2014 conference (an inter-
national conference attended by MDACC and its sister insti-
Fig. 2. Opening ceremony of the new Yonsei Cancer Center building.
Fig. 1. In 2000, an honorary D.M.Sc degree was awarded to Professor 
Hong from his alma mater Yonsei University with the Grand Prize in Medi-
cine.
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tutions), as well as allowing researchers from his alma mater 
to participate in the Sister Institution Network Fund (Fig. 4). 
In 2018, he helped establish the AACR–Korean Cancer Associ-
ation (KCA) joint conference in Seoul. “Some people can be 
very smart but they can also be very selfish,” he said. “Individu-
als are competent but they do not always know how to work 
together. A culture of collaboration and unselfishness should 
be cultivated among young people.”8
Professor Hong passed away on January 2, 2019, at the age 
of 76 years. A memorial service was held at Onnuri Church in 
Newport, California on January 12, 2019 to celebrate his life. 
During his career, he built a colorful personal and profession-
al resume throughout more than 50 years in academic medi-
cine. His work has changed the lives of cancer patients on this 
planet. Given his career as a physician/scientist whose pio-
neering research has resulted in three groundbreaking contri-
butions in cancer medicine, Professor Hong was posthumous-
ly awarded the Order of Civil Merit, Magnolia Medal from the 
Korean government, while the AACR–KCA decided to hold the 
Waun-Ki Hong Memorial Lecture at the AACR-KCA Interna-
tional Conference and Workshop beginning in 2019. The first 
lecturer of Waun-Ki Hong Memorial Lecture at the AACR-KCA 
workshop was Professor Roy H. Herbst of Yale Cancer Center.9 
Professor Hong said he had achieved the American Dream. 
During his life, he helped many and left behind a legacy that 
will endure for generations. Professor Hong himself, a trail-
blazing pioneer and an international hero in the field of cancer 
medicine, is the embodiment of Cancer Medicine at MDACC 
and the Global Oncology Society.3 
Fig. 4. Director’s meeting of the Sister Institutions of Global Academy Program of MDACC.
Fig. 3. Professor Hong visiting the new Yonsei Cancer Center building 
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